Success Metrics

Clinical Success Rate
93.8%

Based on 15 completed trials

Completion Rate
94%(15/16)
Active Trials
2(11%)
Results Posted
20%(3 trials)
Terminated
1(5%)

Phase Distribution

Ph not_applicable
2
11%
Ph phase_3
2
11%
Ph phase_4
3
16%

Phase Distribution

0

Early Stage

0

Mid Stage

5

Late Stage

Phase Distribution7 total trials
Phase 3Large-scale testing
2(28.6%)
Phase 4Post-market surveillance
3(42.9%)
N/ANon-phased studies
2(28.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

88.2%

15 of 17 finished

Non-Completion Rate

11.8%

2 ended early

Currently Active

2

trials recruiting

Total Trials

19

all time

Status Distribution
Active(2)
Completed(15)
Terminated(2)

Detailed Status

Completed15
Active, not recruiting1
Withdrawn1
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
19
Active
2
Success Rate
93.8%
Most Advanced
Phase 4

Trials by Phase

Phase 32 (28.6%)
Phase 43 (42.9%)
N/A2 (28.6%)

Trials by Status

active_not_recruiting15%
withdrawn15%
completed1579%
recruiting15%
terminated15%

Recent Activity

2 active trials
Showing 5 of 19
completed

Comparative Effectiveness of Empagliflozin in the US

NCT03363464
completed

Antidiabetic Medications and Risk of Cancer

NCT07628556
active_not_recruiting

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study

NCT05220917
completed

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors

NCT05768945
completedphase_3

A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients

NCT01242228
View all 19 trials

Clinical Trials (19)

Showing 19 of 19 trials
NCT03363464

Comparative Effectiveness of Empagliflozin in the US

Completed
NCT07628556

Antidiabetic Medications and Risk of Cancer

Completed
NCT05220917

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study

Active Not Recruiting
NCT05768945

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors

Completed
NCT01242228Phase 3

A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients

Completed
NCT06838286

Korean Study on Safety and Effectiveness of OAD Triple Therapy in Type 2 Diabetes

Recruiting
NCT06099067

Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)

Completed
NCT03921242

Comparative Effectiveness of Metformin for Type 2 Diabetes With Chronic Kidney Disease

Completed
NCT04215523

Replication of the DECLARE Diabetes Trial in Healthcare Claims

Completed
NCT04215536

Replication of the EMPAREG Diabetes Trial in Healthcare Claims

Completed
NCT03936010

Replication of the CANVAS Diabetes Trial in Healthcare Claims

Completed
NCT03936049

Replication of the LEADER Diabetes Trial in Healthcare Claims

Completed
NCT03845179Not Applicable

GA 6: The Blood Glucose-lowering Effect of Glucose-dependent Insulinotropic Polypeptide

Completed
NCT04192292Not Applicable

Study of Sulphonylurea Synergy With DPP4 Inhibitors

Completed
NCT04304430

Comparative Effectiveness of Dapagliflozin Versus DPP-4 Inhibitors

Completed
NCT03813316Phase 4

Approaches To Therapy Escalation In T2D

Withdrawn
NCT02207374Phase 3

A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes

Completed
NCT02365233Phase 4

Fatty Liver Study in Patients With Type II Diabetes

Terminated
NCT02027753Phase 4

Efficacy and Safety of Insulin Glargine in Patients With Type 2 Diabetes With Inadequate Control on DPP-4 Inhibitor Therapy

Completed

All 19 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
19